Every one of those 1 sits in a single category, earnings. CorMedix Inc. is most often covered alongside Acorn Energy, Inc., which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CorMedix Inc.
Every one of those 1 sits in a single category, earnings. CorMedix Inc. is most often covered alongside Acorn Energy, Inc., which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. CorMedix Inc. appears in 1 tracked Finance story from March 6, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CorMedix Inc.. Shared-story counts are live from our verified record — not editorial picks.
Acorn Energy and CorMedix both reported Q4 2025 financial results on March 5, 2026, marking a critical transition from development to commercial scaling. While Acorn focuses on high-margin IoT recurring revenue, CorMedix is navigating the complex rollout of its lead product, DefenCath, in the dialysis market.
CorMedix Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.